Have a feature idea you'd love to see implemented?
Let us know!
ENLV Enlivex Therapeutics Ltd
Price (delayed)
$0.841
Market cap
$17.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
-$8.38M
enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib
Highlights
The company's quick ratio has surged by 63% YoY and by 46% QoQ
Enlivex Therapeutics's EPS has increased by 19% YoY and by 15% from the previous quarter
ENLV's equity is down by 36% year-on-year but it is up by 6% since the previous quarter
Key stats
What are the main financial stats of ENLV
Market
Valuations
Earnings
Shares outstanding
20.88M
Market cap
$17.56M
Enterprise value
-$8.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$22.52M
EBITDA
-$21.76M
Free cash flow
-$16.9M
Per share
Balance sheet
Liquidity
EPS
-$1.18
Free cash flow per share
-$0.86
Book value per share
$1.52
Revenue per share
$0
TBVPS
$1.63
Total assets
$31.9M
Total liabilities
$3.34M
Debt
$0
Equity
$28.56M
Working capital
$25.73M
Debt to equity
0
Current ratio
10.06
Quick ratio
9.45
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-60.8%
Return on equity
-71.8%
Return on invested capital
-176%
Return on capital employed
-77.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENLV stock price
How has the Enlivex Therapeutics stock price performed over time
Intraday
-13.83%
1 week
-22.13%
1 month
-45.03%
1 year
-51.67%
YTD
-68.85%
QTD
-49.94%
Financial performance
How have Enlivex Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.1M
Net income
-$22.29M
Gross margin
N/A
Net margin
N/A
Enlivex Therapeutics's net income has increased by 17% YoY and by 14% from the previous quarter
The company's operating income rose by 14% YoY and by 14% QoQ
Growth
What is Enlivex Therapeutics's growth rate over time
Valuation
What is Enlivex Therapeutics stock price valuation
P/E
N/A
P/B
0.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enlivex Therapeutics's EPS has increased by 19% YoY and by 15% from the previous quarter
ENLV's P/B is 63% below its last 4 quarters average of 1.5 and 61% below its 5-year quarterly average of 1.4
ENLV's equity is down by 36% year-on-year but it is up by 6% since the previous quarter
Efficiency
How efficient is Enlivex Therapeutics business performance
The ROIC has plunged by 123% YoY and by 56% from the previous quarter
Enlivex Therapeutics's ROE has decreased by 43% YoY but it has increased by 3.2% from the previous quarter
Enlivex Therapeutics's ROA has decreased by 43% YoY
Dividends
What is ENLV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENLV.
Financial health
How did Enlivex Therapeutics financials performed over time
The company's quick ratio has surged by 63% YoY and by 46% QoQ
The company's current ratio has surged by 63% YoY and by 28% QoQ
ENLV's debt is 100% lower than its equity
ENLV's equity is down by 36% year-on-year but it is up by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.